436 related articles for article (PubMed ID: 29212734)
1. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
Sherman WH; Hecht E; Leung D; Chu K
Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Sherman WH; Chu K; Chabot J; Allendorf J; Schrope BA; Hecht E; Jin B; Leung D; Remotti H; Addeo G; Postolov I; Tsai W; Fine RL
Cancer; 2015 Mar; 121(5):673-80. PubMed ID: 25492104
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Patel M; Hoffe S; Malafa M; Hodul P; Klapman J; Centeno B; Kim J; Helm J; Valone T; Springett G
J Surg Oncol; 2011 Aug; 104(2):155-61. PubMed ID: 21520097
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Tran NH; Sahai V; Griffith KA; Nathan H; Kaza R; Cuneo KC; Shi J; Kim E; Sonnenday CJ; Cho CS; Lawrence TS; Zalupski MM
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):124-133. PubMed ID: 31494181
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Allendorf JD; Lauerman M; Bill A; DiGiorgi M; Goetz N; Vakiani E; Remotti H; Schrope B; Sherman W; Hall M; Fine RL; Chabot JA
J Gastrointest Surg; 2008 Jan; 12(1):91-100. PubMed ID: 17786524
[TBL] [Abstract][Full Text] [Related]
8. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Kluger MD; Rashid MF; Rosario VL; Schrope BA; Steinman JA; Hecht EM; Chabot JA
J Gastrointest Surg; 2018 Feb; 22(2):235-241. PubMed ID: 28895032
[TBL] [Abstract][Full Text] [Related]
9. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Combs SE; Habermehl D; Kessel KA; Bergmann F; Werner J; Naumann P; Jäger D; Büchler MW; Debus J
Ann Surg Oncol; 2014 Aug; 21(8):2801-7. PubMed ID: 24916745
[TBL] [Abstract][Full Text] [Related]
11. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
12. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Sahora K; Kuehrer I; Schindl M; Koelblinger C; Goetzinger P; Gnant M
World J Surg; 2011 Jul; 35(7):1580-9. PubMed ID: 21523499
[TBL] [Abstract][Full Text] [Related]
13. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.
Kim EJ; Ben-Josef E; Herman JM; Bekaii-Saab T; Dawson LA; Griffith KA; Francis IR; Greenson JK; Simeone DM; Lawrence TS; Laheru D; Wolfgang CL; Williams T; Bloomston M; Moore MJ; Wei A; Zalupski MM
Cancer; 2013 Aug; 119(15):2692-700. PubMed ID: 23720019
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
15. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.
Hurt CN; Falk S; Crosby T; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T; Mukherjee S
Br J Cancer; 2017 May; 116(10):1264-1270. PubMed ID: 28376080
[TBL] [Abstract][Full Text] [Related]
16. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Fietkau R; Grützmann R; Wittel UA; Croner RS; Jacobasch L; Neumann UP; Reinacher-Schick A; Imhoff D; Boeck S; Keilholz L; Oettle H; Hohenberger WM; Golcher H; Bechstein WO; Uhl W; Pirkl A; Adler W; Semrau S; Rutzner S; Ghadimi M; Lubgan D
Strahlenther Onkol; 2021 Jan; 197(1):8-18. PubMed ID: 32914237
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
18. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.
Sahora K; Kuehrer I; Eisenhut A; Akan B; Koellblinger C; Goetzinger P; Teleky B; Jakesz R; Peck-Radosavljevic M; Ba'ssalamah A; Zielinski C; Gnant M
Surgery; 2011 Mar; 149(3):311-20. PubMed ID: 20817204
[TBL] [Abstract][Full Text] [Related]
19. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
[TBL] [Abstract][Full Text] [Related]
20. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Bickenbach KA; Gonen M; Tang LH; O'Reilly E; Goodman K; Brennan MF; D'Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2012 May; 19(5):1663-9. PubMed ID: 22130621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
